Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases

Nuclear Medicine Communications

Volumn 33, Issue 7, 2012, Pages 726-732

  Hindorf, Cecilia ^a,d   Chittenden, Sarah ^b   Aksnes, Anne Kirsti ^c   Parker, Chris ^d   Flux, Glenn D ^a  

^a Joint Department of Physics   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Algeta ASA   (Norway)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

223Ra; alpha particles; quantitative imaging; targeted radionuclide therapy

Indexed keywords

RADIUM CHLORIDE RA 223; CHLORIDE; RADIOISOTOPE; RADIUM;

ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; CAMERA; COLLIMATOR; DIAGNOSTIC ACCURACY; DRUG BIOAVAILABILITY; IMAGE QUALITY; QUANTITATIVE ANALYSIS; ALPHA RADIATION; BONE TUMOR; FEASIBILITY STUDY; HUMAN; METASTASIS; SCINTILLATION CAMERA; TREATMENT OUTCOME;

ALPHA PARTICLES; BONE NEOPLASMS; CHLORIDES; FEASIBILITY STUDIES; GAMMA CAMERAS; HUMANS; PHANTOMS, IMAGING; RADIOISOTOPES; RADIUM; TREATMENT OUTCOME;

EID: 84862239106     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328353bb6e     Document Type: Article

References (9)

1. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002; 62:3120-3125.
2. Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW,Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11:4451-4459.
3. Nilsson S, Franzen L, Parker C. Alpha-emitting radium-223: Two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer. Eur J Cancer Suppl 2009; 7:411P-7018.
4. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tenvall J, et al. Bonetargeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8:587-594.
5. Nilsson S, Strang P, Franzen L. A double-blind, randomised dose-response phase II multicenter study of radium-223 for the palliation of painful bone metastases in castration refractory prostate cancer patients. Eur J Cancer Suppl 2009.
6. Parker C, Hoskin P, Pascoe S. A double blind, randomized, dose-finding, phase II, multicentre study of radium-223 for the treatment of patients with metastatic castration refractory prostate cancer (CRPC): Eudra CT number: 2005-003680-22. Eur J Cancer Suppl 2009; 7:406O-7003.
7. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseus sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003; 44:252-259.
8. NEMA. NEMA NU-1: Performance measurements of gamma cameras 2007.
9. Nist. XCOM: Photons cross section data. Available at: Http://www.nist.gov/pml/data/xcom/index.cfm [Accessed 1 March 2007].